Hematologic Toxicity on RTOG 0418: A Phase II Study of Post-operative IMRT for Gynecologic Cancer

Reviewer: Lara Bonner Millar, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de noviembre del 2010

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Stereotactic Body Radiation Less Costly, More Toxic Than IMRT

Mar 19, 2014

SBRT linked to increased genitourinary toxicity in Medicare beneficiaries with prostate cancer

New Rx for Myeloid Malignancies Moves to Phase II Clinical Trials

Nov 29, 2015

Phase I trial involving 47 patients identified maximum tolerated dose of 400 mg once daily

Low Late Toxicity With Radiation Post Prostatectomy

Nov 29, 2015

Study finds approximately 1 percent of men have grade three and four complications

From the National Cancer Institute